
Cooper Companies (COO) Stock Forecast & Price Target
Cooper Companies (COO) Analyst Ratings
Bulls say
CooperCompanies demonstrated robust financial performance, with the operating margin increasing to 27.0%, surpassing consensus estimates by 120 basis points year-over-year. The company's forecast for fiscal year 2026 free cash flow indicates strong growth expectations, projecting a range of $575-625 million, which reflects a year-over-year increase of 33-44%. Furthermore, the continued demand for Paragard, alongside steady growth in CooperVision and improving trends in CooperSurgical, presents promising potential for revenue and earnings per share growth moving forward.
Bears say
Cooper Companies is experiencing downward pressure on its financial outlook, with organic revenue growth estimates for FY26 being revised from +5.3% to +4.9% year-over-year, primarily hindered by intense competition from e-commerce vendors in the Asia-Pacific region. The company's gross margin declined by 80 basis points to 66.2%, below consensus expectations, due to tariffs and an unfavorable product mix, which raises concerns about overall profitability. Additionally, both the CooperVision segment and the fertility sales unit have shown significant weaknesses, particularly in China and EMEA, with crucial indicators such as low single-digit revenue growth and flat operating margins suggesting potential stagnation in earnings growth.
This aggregate rating is based on analysts' research of Cooper Companies and is not a guaranteed prediction by Public.com or investment advice.
Cooper Companies (COO) Analyst Forecast & Price Prediction
Start investing in Cooper Companies (COO)
Order type
Buy in
Order amount
Est. shares
0 shares